A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults

Recruiting

Phase 2

VZV modRNAA Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults

Sponsor:

Pfizer

Code:

NCT05703607

Conditions

Shingles

Herpes Zoster Infection

Human

Eligibility Criteria

Sex: All

Age: 50 - 70+

Healthy Volunteers: Accepted

Interventions

Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection

Candidate 1: PF-07915234: VZV modRNA Suspension for Injection

Candidate 2: PF-07921188: VZV modRNA Suspension for Injection

Candidate 3: PF-07921186: VZV modRNA Suspension for Injection

Shingrix

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-18. This information was provided to ClinicalTrials.gov by Pfizer on 2025-10-16.